Compare BRCB & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | ELTX |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 185.4M |
| IPO Year | N/A | 2014 |
| Metric | BRCB | ELTX |
|---|---|---|
| Price | $8.16 | $2.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $24.83 | $18.00 |
| AVG Volume (30 Days) | 399.9K | ★ 4.0M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | $30.74 | N/A |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.11 | $2.66 |
| 52 Week High | $30.40 | $16.00 |
| Indicator | BRCB | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 34.70 |
| Support Level | $7.15 | $2.72 |
| Resistance Level | $8.79 | $9.76 |
| Average True Range (ATR) | 0.56 | 0.48 |
| MACD | 0.09 | 0.15 |
| Stochastic Oscillator | 59.15 | 5.85 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.